Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LONITEN vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arteries. It reduces peripheral vascular resistance and blood pressure by hyperpolarizing vascular smooth muscle cells via activation of ATP-sensitive potassium channels.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
FDA-approved for treatment of hypertension (as a third-line agent in patients who have not responded to other antihypertensives),Off-label: treatment of androgenetic alopecia (topical formulation; oral low-dose minoxidil is also used for hair loss)
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
10 mg orally twice daily, titrated to 40 mg twice daily for hypertension; for heart failure, start at 2.5-5 mg orally twice daily, max 20 mg twice daily.
250 mg orally twice daily
Terminal elimination half-life: 4.2 hours (range 3.5–5.5); clinically, half-life extends to 14–23 hours after chronic dosing due to drug accumulation.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Primarily metabolized by the liver via glucuronidation (UGT1A1) to inactive metabolites; less than 20% excreted unchanged in urine.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal: 85% (12% unchanged, 73% as glucuronide conjugates); biliary/fecal: 3%
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
No significant plasma protein binding (<1%); binds to vasular smooth muscle tissue.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
1.5 L/kg (range 1.2–2.0); large Vd indicates extensive tissue binding, primarily to arteriolar smooth muscle.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 95% (rapidly and completely absorbed).
70-90% (oral); 100% (IV).
No dose adjustment needed for mild to moderate renal impairment (GFR >30 m L/min). For severe renal impairment (GFR <30 m L/min), reduce dose by 50% and monitor closely.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
No specific Child-Pugh based guidelines; use with caution in severe hepatic impairment as drug may accumulate. Reduce initial dose by 50% in Child-Pugh class C.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
For hypertension: 0.1-0.2 mg/kg orally once daily, titrate to max 0.5 mg/kg/day divided every 12-24 hours, max 50 mg/day.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at lower end of dosing range (2.5-5 mg twice daily) due to increased sensitivity; titrate slowly. Monitor for orthostatic hypotension and renal function.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
Must be administered under close medical supervision; may cause pericardial effusion, occasionally progressing to cardiac tamponade, especially in patients with renal impairment or those on dialysis.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Monitor for pericardial effusion and tamponade; discontinue if effusion occurs and treat appropriately.,May cause severe fluid retention and congestive heart failure; administer with a diuretic.,Can exacerbate angina; use with caution in patients with coronary artery disease.,Hypertrichosis (excessive hair growth) is common; reversible upon discontinuation.,Monitor blood pressure closely; avoid abrupt withdrawal to prevent rebound hypertension.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to minoxidil or any component of the formulation.,Pheochromocytoma (due to risk of catecholamine release).
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-sodium foods and excessive alcohol intake, which can exacerbate fluid retention and hypertension. No specific food interactions with minoxidil itself, but maintain a balanced diet as part of hypertension management.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Pregnancy Category C. Fetal risks: First trimester - limited human data; animal studies show fetal resorptions and cardiovascular anomalies at high doses. Second/third trimesters - possible fetal hypotension, oligohydramnios, and hypertrichosis. Use only if benefit outweighs risk.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Excreted in breast milk; M/P ratio unknown. Avoid use while breastfeeding due to potential adverse effects (e.g., hypotension) in the infant.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No specific dose adjustment recommended; pharmacokinetic changes in pregnancy may require titration based on maternal response and tolerability.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Initiate at low doses (2.5 mg BID) and titrate slowly to avoid severe hypotension. Monitor for pericardial effusion, especially in patients with renal impairment. Use with a diuretic and beta-blocker to prevent reflex tachycardia and fluid retention. Abrupt discontinuation can cause rebound hypertension.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,You may experience dizziness or lightheadedness, especially when standing up; rise slowly.,Report unusual weight gain, swelling in ankles or legs, shortness of breath, or chest pain.,You may notice increased hair growth on face, arms, or back; this is reversible after stopping.,Avoid alcohol and excessive salt intake to help control blood pressure.,Use sunscreen and protective clothing as you may become more sensitive to sunlight.,Do not take over-the-counter medications without checking with your doctor.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LONITEN vs ALDOCLOR-250, answered by our medical review team.
LONITEN is a Antihypertensive that works by Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arteries. It reduces peripheral vascular resistance and blood pressure by hyperpolarizing vascular smooth muscle cells via activation of ATP-sensitive potassium channels.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LONITEN and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LONITEN is: 10 mg orally twice daily, titrated to 40 mg twice daily for hypertension; for heart failure, start at 2.5-5 mg orally twice daily, max 20 mg twice daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LONITEN and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LONITEN is classified as Category C. Pregnancy Category C. Fetal risks: First trimester - limited human data; animal studies show fetal resorptions and cardiovascular anomalies at high doses. Second/third trimesters -. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.